deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT03823768

Envarsus Neurotoxicity Burden in Liver Transplant Patients

The Effect of Conversion to Once-Daily Envarsus® on the Neurologic Toxicity Burden in Liver Transplant Recipients

Sponsor: Medical University of South Carolina

Conditions Liver Transplant; Complications Neurotoxicity
Interventions Envarsus Tacrolimus Immediate release
Updated 17 times since 2019 Last updated: Mar 12, 2025 Started: Jan 31, 2020 Primary completion: Apr 30, 2023 Completion: Jan 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Liver Transplant; Complications and Neurotoxicity, this trial is completed. The trial is conducted by Medical University of South Carolina and has accumulated 17 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Jan 2020 · 3 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2022 · 14 months · monthly snapshot~May 2022 – ~Jun 2023 · 13 months · monthly snapshot~Jun 2023 – ~Dec 2023 · 6 months · monthly snapshot~Dec 2023 – ~Apr 2024 · 4 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – present · 15 months · monthly snapshot

Change History

17 versions recorded

  1. Apr 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE4

    Status: Active Not Recruiting → Completed

  5. Dec 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE4

▶ Show 12 earlier versions

  1. Jun 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE4

  2. May 2022 — Jun 2023 [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

  3. Mar 2021 — May 2022 [monthly]

    Recruiting PHASE4

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE4

  5. Mar 2020 — Jan 2021 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  6. Jan 2020 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE4

  7. Oct 2019 — Jan 2020 [monthly]

    Not Yet Recruiting PHASE4

  8. Aug 2019 — Oct 2019 [monthly]

    Not Yet Recruiting PHASE4

  9. Jun 2019 — Aug 2019 [monthly]

    Not Yet Recruiting PHASE4

  10. Apr 2019 — Jun 2019 [monthly]

    Not Yet Recruiting PHASE4

  11. Mar 2019 — Apr 2019 [monthly]

    Not Yet Recruiting PHASE4

  12. Feb 2019 — Mar 2019 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Medical University of South Carolina
  • Veloxis Pharmaceuticals
Data source: Medical University of South Carolina

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations